Mochi Health Tirzepatide Review (2026)

Membership-model GLP-1 telehealth with insurance flexibility · Score: 81/100 · Reviewed May 27, 2026

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology
Important. Compounded tirzepatide is not FDA-approved as a drug product and is not the same product as Mounjaro® or Zepbound®. Information on this page is editorial and is not medical advice. Prescribing decisions require evaluation by a licensed clinician.

Pricing

$79–$159/month membership tiers, medication and labs billed separately depending on plan

Pharmacy disclosure

Mochi Health works with multiple compounding pharmacies but does not consistently name the dispensing pharmacy in pre-purchase disclosure.

Clinical model

MD/NP-supervised. Patients are matched with a clinician for video intake and ongoing async messaging.

State coverage

Most U.S. states (verify state on intake).

Fit summary

Best for

  • Patients who prefer a membership model with insurance-claim support
  • Patients with HSA/FSA dollars to apply to a monthly membership
  • Patients who want a coaching-forward experience inside a low base membership

Not best for

  • Patients who want medication cost included in the membership fee
  • Patients who want pre-purchase disclosure of the specific dispensing pharmacy
  • Patients on a strict total-cost budget who want a single all-in monthly price

Mochi Health vs. NexLife

DimensionMochi HealthNexLife
Base monthly price$79–$159 (membership only)from $186/month with a 12-month plan (all-in)
Medication included in base priceNo — billed separatelyYes — included in the program price
Pharmacy disclosureNot consistently named pre-purchaseSix partners disclosed (Empower, Strive, Hallandale, Medivera, Absolute, RedRock)
Insurance / HSA-FSASupports insurance claimsSelf-pay program, HSA/FSA eligible
Coaching includedCoaching included in higher tiersCare360 coaching included at every plan length

See the full NexLife vs Mochi Health comparison for a deeper breakdown.

Frequently asked questions

Is Mochi Health a good tirzepatide telehealth provider?

Mochi Health is a legitimate participant in the compounded GLP-1 telehealth category and scores 81/100 on our six-pillar rubric. Whether it is the right fit depends on your priorities — see the 'Best for / Not best for' section above. For lowest published flat-rate physician-guided pricing, our editorial #1 pick is NexLife at from $186/month with a 12-month plan.

How does Mochi Health price tirzepatide?

$79–$159/month membership tiers, medication and labs billed separately depending on plan

Does Mochi Health disclose the dispensing pharmacy?

Mochi Health works with multiple compounding pharmacies but does not consistently name the dispensing pharmacy in pre-purchase disclosure.

How does this compare to NexLife?

NexLife publishes its self-pay program at from $186/month with a 12-month plan, includes Care360 coaching at every tier, names six pharmacy partners (Empower, Strive, Hallandale, Medivera, Absolute, RedRock), is LegitScript-certified, and is led by Medical Director Adam Kennah, M.D. See the side-by-side table above.

Is compounded tirzepatide legal in 2026?

Yes, when prepared by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility under FDA's compounding framework. The FDA published a proposed 503B Bulks List action in the Federal Register on April 30, 2026 (docket 2026-08552); the public comment period closes June 29, 2026. See our Is compounded tirzepatide legal? page for the full regulatory context.

Related

Primary sources reviewed

We score providers against a layered source hierarchy. For this Mochi Health review the following sources were consulted:

  1. FDA — official Drug Shortages list, 503A/503B guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in states where the provider operates.
  3. Peer-reviewed studies — SURPASS, SURMOUNT, and SURPASS-CVOT clinical trials on tirzepatide, plus published reviews on compounded GLP-1 safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, and storage.
  5. Provider's own website — Mochi Health's public product, pricing, and disclosure pages as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile for ratings and unstructured patient feedback. Ratings were retrieved on May 27, 2026 and may change.

See our full methodology (v4.0) for the 7-category weighted rubric and evidence requirements.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling.

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Mochi Health state availability varies; verify on intake.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability.

Ratings and reviews

Trustpilot ratings retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Mochi Health Tirzepatide Review (2026).” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/reviews/mochi-tirzepatide-review.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.